Evaluation of genetic alterations in cancer-related genes in lung and brain tumors from B6C3F1 mice exposed to 1,3-butadiene or chloroprene

Chemico-Biological Interactions

Volumn 166, Issue 1-3, 2007, Pages 112-120

  Ton, Thai Vu ^a   Hong, Hue Hua ^a   Devereux, Theodora R ^a   Melnick, Ronald L ^a   Sills, Robert C ^a   Kim, Yongbaek ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

1,3 Butadiene; Brain; Carcinogenesis; Chloroprene; K ras; Loss of heterozygosity; Lung; Mutation; p16; p53; Tumor

Indexed keywords

1,3 BUTADIENE; CHLOROPRENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; CHEMICAL CARCINOGENESIS; CHEMICAL MUTAGENESIS; CHROMOSOME 6; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; LUNG CARCINOGENESIS; LUNG TUMOR; MALE; MOUSE; NONHUMAN; ONCOGENE K RAS; P16 GENE; TUMOR SUPPRESSOR GENE;

ALLELES; ANIMALS; BRAIN NEOPLASMS; BUTADIENES; CARCINOGENS; CHLOROPRENE; CHROMOSOMES, MAMMALIAN; DNA ADDUCTS; FEMALE; GENES, NEOPLASM; GENES, RAS; HUMANS; INHALATION EXPOSURE; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MALE; MICE; MUTAGENESIS;

MUS;

EID: 33947167501     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2006.04.015     Document Type: Article

References (56)

1. National Toxicology Program (NTP), Toxicology and Carcinogenesis Studies of 1,3-Butadiene (CAS no. 106-99-0) in B6C3F1 Mice (Inhalation Studies), Technical Report Series No. 434. NIH Publication No. 93-3165, US Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC, 1993.
2. National Toxicology Program (NTP), Toxicology and Carcinogenesis Studies of Chloroprene (CAS No. 126-99-8) in F344/N Rats and B6C3F1 Mice (Inhalation Studies), Technical Report Series No. 467. NIH Publication No. 98-3957, US Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC, 1998.
3. Himmelstein M.W., Acquavella J.F., Recio L., Medinsky M.A., and Bond J.A. Toxicology and epidemiology of 1,3-butadiene. Crit. Rev. Toxicol. 27 (1997) 1-108
4. Huff J.E., Melnick R.L., Solleveld H.A., Haseman J.K., Powers M., and Miller R.A. Multiple organ carcinogenicity of 1,3-butadiene in B6C3F1 mice after 60 weeks of inhalation exposure. Science 227 (1985) 548-549
5. Melnick R.L., Huff J., Chou B.J., and Miller R.A. Carcinogenicity of 1,3-butadiene in C57BL/6 × C3H F1 mice at low exposure concentrations. Cancer Res. 50 (1990) 6592-6599
6. Melnick R.L., Sills R.C., Portier C.J., Roycroft J.H., Chou B.J., Grumbein S.L., and Miller R.A. Multiple organ carcinogenicity of inhaled chloroprene (2-chloro-1,3-butadiene) in F344/N rats and B6C3F1 mice and comparison of dose-response with 1,3-butadiene in mice. Carcinogenesis 20 (1999) 867-878
7. National Toxicology Program (NTP), Toxicology and Carcinogenesis Studies of 1,3-Butadiene (CAS no. 106-99-0) in B6C3F1 Mice (Inhalation Studies), Technical Report Series No. 288. NIH Publication No. 84-2544, US Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC, 1984.
8. National Toxicology Program, Ninth Report on Carcinogens, US DHHS, Research Triangle Park, NC, 2000.
9. Santos-Burgoa C., Matanoski G.M., Zeger S., and Schwartz L. Lymphohematopoietic cancer in styrene-butadiene polymerization workers. Am. J. Epidemiol. 136 (1992) 843-854
10. Macaluso M., Larson R., Delzell E., Sathiakumar N., Hovinga M., Julian J., Muir D., and Cole P. Leukemia and cumulative exposure to butadiene, styrene and benzene among workers in the synthetic rubber industry. Toxicology 113 (1996) 190-202
11. Shelby M.D. Results of NTP-sponsored mouse cytogenetic studies on 1,3-butadiene, isoprene, and chloroprene. Environ. Health Perspect. 86 (1990) 71-73
12. Meng Q., Henderson R.F., Chen T., Heflich R.H., Walker D.M., Bauer M.J., Reilly A.A., and Walker V.E. Mutagenicity of 1,3-butadiene at the Hprt locus of T-lymphocytes following inhalation exposure of female mice and rats. Mutat. Res. 429 (1999) 107-125
13. Tretvakova N., Sangaiah R., Yen T.Y., and Swenberg J.A. Synthesis, characterization, and in vitro quantitation of N-7-guanine adducts of diepoxybutane. Chem. Res. Toxicol. 10 (1997) 779-785
14. Powley M.W., Li Y., Upton P.B., Walker V.E., and Swenberg J.A. Quantification of DNA and hemoglobin adducts of 3,4-epoxy-1,2-butanediol in rodents exposed to 3-butene-1,2-diol. Carcinogenesis 26 (2005) 1573-1580
15. Recio L., Steen A.M., Pluta L.J., Meyer K.G., and Saranko C.J. Mutational spectrum of 1,3-butadiene and metabolites 1,2-epoxybutene and 1,2,3,4-diepoxybutane to assess mutagenic mechanisms. Chem. Biol. Interact. 135-136 (2001) 325-341
16. Bartsch H., Malaveille C., Montesano R., and Tomatis L. Tissue mediated mutagenicity of cinylidene chloride and 2-chlorobutadiene in Salmonella typhimurium. Nature 255 (1975) 641-643
17. Zeiger E., Anderson B., Haworth S., Lawlor T., Mortelmans K., and Speck W. Salmonella mutagenicity tests. III. Results from the testing of 255 chemicals. Environ. Mutagen. 9 Suppl. (1987) 1-110
18. Melnick R.L., and Sills R.C. Comparative carcinogenicity of 1,3-butadiene, isoprene, and chloroprene in rats and mice. Chem. Biol. Interact. 135-136 (2001) 27-42
19. Anderson M.W., Reynolds S., You M., and Maronpot R. Role of proto-oncogene activation in carcinogenesis. Environ. Health Perspect. 98 (1992) 12-24
20. Sills R.C., Boorman G.A., Neal J.E., Hong H.L., and Devereux T.R. Mutations in ras genes in experimental tumours of rodents. IARC Sci. Publ. 146 (1999) 55-86
21. Barrett J.C., and Wiseman R.W. Cellular and molecular mechanisms of multistep carcinogenesis: relevance to carcinogen risk assessment. Environ. Health Perspect. 76 (1987) 65-70
22. Le Calvez F., Mukeria A., Hunt J.D., Kelm O., Hung R.J., Taniere P., Brennan P., Boffetta P., Zaridze D.G., and Hainaut P. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res. 65 (2005) 5076-5083
23. Hua V., Wang W., and Duesberg P. Dominant transformation by mutated human ras genes in vitro requires more than 100 times higher expression than is observed in cancers. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 9614-9619
24. Zhang S., Wang Y., Vikis H.G., Johnson L., Liu G., Li J., Anderson M.W., Sills R.C., Hong H.L., Devereux T.R., Jacks T., Guan K.-L., and You M. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat. Genet. 29 (2001) 25-33
25. Devereux T.R., Holliday W., Anna C., Ress N., Roycroft J.H., and Sills R.C. Map kinase activation correlates with K-ras mutation and loss of heterozygosity on chromosome 6 in alveolar bronchiolar carcinomas from B6C3F1 mice exposed to vanadium pentoxide for 2 years. Carcinogenesis 23 (2002) 1737-1743
26. Haseman J.K., Elwell M.R., and Hailey J.R. Neoplasm incidences in B6C3F1 mice: NTP historical data. In: Maronpot R.R. (Ed). Pathology of the Mouse (1999), Cache River Press, Vienna, IL 679-690
27. Kim Y., Hong H.L., Lachat Y., Clayton N.P., Devereux T.R., Melnick R.L., Hegi M., and Sills R.C. Genetic alterations in brain tumors following 1,3-butadiene exposure in B6C3F1 mice. Toxicol. Pathol. 33 (2005) 307-312
28. Holland E.C. Gliomagenesis: genetic alterations and mouse models. Nat. Rev. Genet. 2 (2001) 120-129
29. Schwab M., Westermann F., Hero B., and Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol. 4 (2003) 472-480
30. Rasheed B.K., McLendon R.E., Herndon J.E., Friedman H.S., Friedman A.H., Bigner D.D., and Bigner S.H. Alterations of the TP53 gene in human gliomas. Cancer Res. 54 (1994) 1324-1330
31. He J., Olson J.J., and James C.D. Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res. 55 (1995) 4833-4836
32. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., and Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997) 1943-1947
33. Ekstrand A.J., Longo N., Hamid M.L., Olson J.J., Liu L., Collins V.P., and James C.D. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 9 (1994) 2313-2320
34. Lastowska M., Cullinane C., Variend S., Cotterill S., Bown N., O'Neill S., Mazzocco K., Roberts P., Nicholson J., Ellershaw C., Pearson A.D., and Jackson M.S. Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J. Clin. Oncol. 19 (2001) 3080-3090
35. Tonini G.P., and Romani M. Genetic and epigenetic alterations in neuroblastoma. Cancer Lett. 197 (2003) 69-73
36. Ichimura K., Bolin M.B., Goike H.M., Schmidt E.E., Moshref A., and Collins V.P. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res. 60 (2000) 417-424
37. Hong H.H., Devereux T.R., Melnick R.L., Moomaw C.R., Boorman G.A., and Sills R.C. Mutations of ras protooncogenes and p53 tumor suppressor gene in cardiac hemangiosarcomas from B6C3F1 mice exposed to 1,3-butadiene for 2 years. Toxicol. Pathol. 28 (2000) 529-534
38. Goodrow T.L., Reynolds S., Maronpot R., and Anderson M.W. Activation of K-ras by codon 13 mutations in C57BL/6 × C3H F1 mouse tumors induced by exposure to 1,3-butadiene. Cancer Res. 50 (1990) 4818-4823
39. Citti L., Gervasi P.G., Turchi G., Bellucci G., and Bianchini R. The reaction of 3,4-epoxy-1-butene with deoxyguanosine and DNA in vitro: synthesis and characterization of the main adducts. Carcinogenesis 5 (1984) 47-52
40. Leuratti C., Jones N.J., Marafante E., Kostiainen R., Peltonen K., and Waters R. DNA damage induced by environmental carcinogen butadiene: identification of a diepoxybutane-adenine adduct and its detection by 32P-postlabelling. Carcinogenesis 15 (1994) 1903-1910
41. Boysen G., Georgieva N.I., Upton P.B., Jayaraj K., Li Y., Walker V.E., and Swenberg J.A. Analysis of diepoxide-specific cyclic N-terminal globin adducts in mice and rats after inhalation exposure to 1,3-butadiene. Cancer Res. 64 (2004) 8517-8520
42. Sills R.C., Hong H.L., Melnick R.L., Boorman G.A., and Devereux T.R. High frequency of codon 61 K-ras A-->T transversions in lung and Harderian gland neoplasms of B6C3F1 mice exposed to chloroprene (2-chloro-1,3-butadiene) for 2 years, and comparisons with the structurally related chemicals isoprene and 1,3-butadiene. Carcinogenesis 20 (1999) 657-662
43. Munter T., Cottrell L., Hill S., Kronberg L., Watson W.P., and Golding B.T. Identification of adducts derived from reactions of (1-chloroethenyl)oxirane with nucleosides and calf thymus DNA. Chem. Res. Toxicol. 15 (2002) 1549-1560
44. Li J., Zhang Z., Dai Z., Plass C., Morrison C., Wang Y., Wiest J.S., Anderson M.W., and You M. LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer. Oncogene 22 (2003) 1243-1246
45. Tice R.R., Boucher R., Luke C.A., and Shelby M.D. Comparative cytogenetic analysis of bone marrow damage induced in male B6C3F1 mice by multiple exposures to gaseous 1,3-butadiene. Environ. Mutagen. 9 (1987) 235-250
46. Bartsch H., Malaveille C., Barbin A., and Planche G. Mutagenic and alkylating metabolites of halo-ethylenes, chlorobutadienes and dichlorobutenes produced by rodent or human liver tissues; evidence for oxirane formation by P-450 linked microsomal monooxygenases. Arch. Toxicol. 41 (1979) 249-277
47. Tice R.R., Boucher R., Luke C.A., Paquette D.E., Melnick R.L., and Shelby M.D. Chloroprene and isoprene: cytogenetic studies in mice. Mutagenesis 3 (1988) 141-146
48. Kleihues P., and Cavenee W.K. Pathology and Genetics of Tumors of the Nervous System (2000), IARC Press, Lyon
49. Melnick R.L. Carcinogenicity and mechanistic insights on the behavior of epoxides and epoxide-forming chemicals. Ann. N.Y. Acad. Sci. 982 (2002) 177-189
50. L.S. Trukhanova, H.H. Hong, R.C. Sills, A.D. Bowser, B. Gaul, G.A. Boorman, V.S. Turusov, T.R. Devereux, D. Dixon, Predominant p53 G-->A transition mutation and enhanced cell proliferation in uterine sarcomas of CBA mice treated with 1,2-dimethylhydrazine, Toxicol. Pathol. 26 (1998) 367-374.
51. Watanabe K., Tachibana O., Sata K., Yonekawa Y., Kleihues P., and Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 6 (1996) 217-223 discussion 23-24
52. Fulci G., Labuhn M., Maier D., Lachat Y., Hausmann O., Hegi M.E., Janzer R.C., Merlo A., and Van Meir E.G. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 19 (2000) 3816-3822
53. Herzog C.R., Noh S., Lantry L.E., Guan K.L., and You M. Cdkn2a encodes functional variation of p16INK4a but not p19ARF, which confers selection in mouse lung tumorigenesis. Mol. Carcinog. 25 (1999) 92-98
54. Zhang Z., Wang Y., Herzog C.R., Liu G., Lee H.W., DePinho R.A., and You M. A strong candidate gene for the Papg1 locus on mouse chromosome 4 affecting lung tumor progression. Oncogene 21 (2002) 5960-5966
55. Bachoo R.M., Maher E.A., Ligon K.L., Sharpless N.E., Chan S.S., You M.J., Tang Y., DeFrances J., Stover E., Weissleder R., Rowitch D.H., Louis D.N., and DePinho R.A. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1 (2002) 269-277
56. Oda H., Zhang S., Tsurutani N., Shimizu S., Nakatsuru Y., Aizawa S., and Ishikawa T. Loss of p53 is an early event in induction of brain tumors in mice by transplacental carcinogen exposure. Cancer Res. 57 (1997) 646-650